Bruker (BRKR) & Accelerate Diagnostics (AXDX) Head-To-Head Contrast

Bruker (NASDAQ: BRKR) and Accelerate Diagnostics (NASDAQ:AXDX) are both computer and technology companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, profitability, institutional ownership, risk, dividends, valuation and earnings.

Dividends

Bruker pays an annual dividend of $0.16 per share and has a dividend yield of 0.5%. Accelerate Diagnostics does not pay a dividend. Bruker pays out 13.2% of its earnings in the form of a dividend.

Volatility & Risk

Bruker has a beta of 1.17, indicating that its stock price is 17% more volatile than the S&P 500. Comparatively, Accelerate Diagnostics has a beta of 2.04, indicating that its stock price is 104% more volatile than the S&P 500.

Earnings and Valuation

This table compares Bruker and Accelerate Diagnostics’ gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Bruker $1.77 billion 2.59 $78.60 million $1.21 24.21
Accelerate Diagnostics $4.18 million 284.11 -$64.02 million ($1.16) -18.97

Bruker has higher revenue and earnings than Accelerate Diagnostics. Accelerate Diagnostics is trading at a lower price-to-earnings ratio than Bruker, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Bruker and Accelerate Diagnostics, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Bruker 2 8 1 0 1.91
Accelerate Diagnostics 0 2 0 0 2.00

Bruker currently has a consensus price target of $32.80, suggesting a potential upside of 11.98%. Accelerate Diagnostics has a consensus price target of $29.50, suggesting a potential upside of 34.09%. Given Accelerate Diagnostics’ stronger consensus rating and higher probable upside, analysts plainly believe Accelerate Diagnostics is more favorable than Bruker.

Profitability

This table compares Bruker and Accelerate Diagnostics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Bruker 4.63% 27.04% 10.69%
Accelerate Diagnostics -1,568.29% -51.23% -44.59%

Institutional and Insider Ownership

65.5% of Bruker shares are held by institutional investors. Comparatively, 47.2% of Accelerate Diagnostics shares are held by institutional investors. 35.2% of Bruker shares are held by insiders. Comparatively, 49.3% of Accelerate Diagnostics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Bruker beats Accelerate Diagnostics on 10 of the 16 factors compared between the two stocks.

About Bruker

Bruker Corporation manufactures and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates in two segments, Bruker Scientific Instruments, and Bruker Energy & Supercon Technologies. It offers life science tools based on magnetic resonance technology; life science mass spectrometry and ion mobility spectrometry systems; infrared spectroscopy and radiological/nuclear detectors for chemical, biological, radiological, nuclear, and explosive detection in emergency response, homeland security, and defense applications; and research, analytical, and process analysis instruments and solutions based on infrared and Raman molecular spectroscopy technologies. The company also provides X-ray instruments, atomic force microscopy instrumentation, fluorescence optical microscopy instruments, analytical tools for electron microscopes and X-ray metrology, and defect-detection equipment for semiconductor process control, as well as handheld, portable, and mobile X-ray fluorescence spectrometry instruments and spark optical emission spectroscopy systems. In addition, it offers superconducting and non-superconducting materials and devices. The company serves pharmaceutical, biotechnology and diagnostics, chemical, food and beverage, clinical, polymer, nanotechnology, semiconductor, and industrial companies; nonprofit laboratories; contract research organizations, academic institutions, medical schools, nonprofit or for-profit forensics, agriculture, food and beverage safety, environmental and clinical microbiology laboratories, hospitals, and government departments and agencies; and raw material manufacturers, and other businesses involved in materials analysis. It markets its products through direct sales forces, distributors, independent sales representatives, and other representatives. Bruker Corporation was founded in 1991 and is headquartered in Billerica, Massachusetts.

About Accelerate Diagnostics

Accelerate Diagnostics, Inc., an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States. It offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms, as well as yeast. The company was formerly known as Accelr8 Technology Corporation and changed its name to Accelerate Diagnostics, Inc. in December 2012. Accelerate Diagnostics, Inc. was founded in 1982 and is headquartered in Tucson, Arizona.

Receive News & Ratings for Bruker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bruker and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply